{"analyses":[{"ciLowerLimit":"41.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"58.5","estimateComment":"Enzalutamide response rate minus bicalutamide response rate.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Difference in rates","paramValue":"50.0","statisticalComment":"Comparison of the 2 treatment groups using the Cochran-Mantel-Haenszel mean score test stratified by disease stage at study entry.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.0","upperLimit":"86.5","value":"81.3"},{"groupId":"OG001","lowerLimit":"24.8","upperLimit":"38.3","value":"31.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"195"}],"units":"Participants"}],"description":"PSA response was defined as a reduction in PSA of at least 50% from baseline at any post baseline assessment confirmed by a second PSA assessment at least 3 weeks later.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received enzalutamide 160 mg, self-administered as four 40-mg capsules, once per day by mouth and 1 bicalutamide-placebo capsule in DB phase.","id":"OG000","title":"Enzalutamide"},{"description":"Participants received bicalutamide 50 mg, self-administered as 1 capsule, once per day by mouth and 4 enzalutamide-placebo capsules in DB phase.","id":"OG001","title":"Bicalutamide"}],"paramType":"NUMBER","populationDescription":"Evaluable intent-to-treat population: all participants randomly assigned to study treatment and had a baseline and at least 1 post baseline PSA measurement.","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.","title":"Percentage of Participants With a PSA Response ≥ 50%","type":"SECONDARY","unitOfMeasure":"percentage of participants"}